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Introduction: spinal muscular atrophy
Spinal muscular atrophy (SMA), which is characterized by
degeneration of spinal cord lower motor neurons that leads to
proximal muscle wasting and paralysis, is a common autosomal
recessive disease affecting 1 in 6000 live births (Pearn, 1978;
Lefebvre et al., 1995). The disease is classified into four types (Type
I-IV) based on the age of onset and clinical symptoms. Although
there is a wide spectrum of clinical severity, in its commonest and
most severe form (Type I), SMA leads to death in infancy from
respiratory muscle weakness. Even patients with non-fatal forms
of SMA (Types III and IV) are considerably disabled and there is
an urgent need for treatments that slow or arrest progression of
the disease.
The complex molecular genetic basis of SMA raises challenges
for modeling the disease in other species. Owing to an
intrachromosomal duplication event on chromosome 5q13,
humans possess two copies of the gene encoding ‘survival motor
neuron’ (SMN) – SMN1 and SMN2 (Lefebvre et al., 1995). Deletion
or gene conversion events render SMA patients homozygously null
for SMN1, whereas they retain a variable number of SMN2 copies.
A critical C-to-T transition six base pairs into exon 7, present in
all copies of the SMN2 gene described in humans to date, causes
aberrant splicing of 80-90% of SMN2 transcripts, causing them to
lack exon 7 (SMN7) and therefore produce a protein product with
reduced stability (Lorson et al., 1999; Monani et al., 1999; Lorson
and Androphy, 2000). SMN levels generally correlate with disease
severity (Coovert et al., 1997; Lefebvre et al., 1997) and, because
complete loss of SMN is lethal, SMA only arises as a disease in
humans owing to the presence of SMN2, which provides sufficient
residual full-length protein for cellular viability (McAndrew et al.,
1997; Feldkötter et al., 2002; Mailman et al., 2002). SMA is therefore
a disease of low levels of protein and not total ablation, a situation
that any model system, either in vitro or in vivo, must reproduce
in order to provide meaningful insights.
SMN is widely and constitutively expressed, and has been
implicated in a range of cellular processes, of which small nuclear
ribonucleoprotein (snRNP) assembly is currently the best
characterized (Fischer et al., 1997; Liu et al., 1997; Meister et al.,
2001; Pellizzoni et al., 2002). Owing to the high degree of
evolutionary conservation of the gene encoding SMN, the effects
of SMN protein depletion have been modeled in diverse organisms,
including in the invertebrates Caenorhabditis elegans (Briese et al.,
2009; Sleigh et al., 2011) and Drosophila melanogaster (Chan et al.,
2003; Chang et al., 2008), and the vertebrates Danio rerio
(McWhorter et al., 2003; Boon et al., 2009) and Mus musculus
(Hsieh-Li et al., 2000; Monani et al., 2000; Le et al., 2005). Zebrafish
and the invertebrate models are well suited to large-scale screening
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Spinal muscular atrophy (SMA), which is caused by inactivating mutations in the survival motor neuron 1 (SMN1) gene,
is characterized by loss of lower motor neurons in the spinal cord. The gene encoding SMN is very highly conserved in
evolution, allowing the disease to be modeled in a range of species. The similarities in anatomy and physiology to the
human neuromuscular system, coupled with the ease of genetic manipulation, make the mouse the most suitable
model for exploring the basic pathogenesis of motor neuron loss and for testing potential treatments. Therapies that
increase SMN levels, either through direct viral delivery or by enhancing full-length SMN protein expression from the
SMN1 paralog, SMN2, are approaching the translational stage of development. It is therefore timely to consider the role
of mouse models in addressing aspects of disease pathogenesis that are most relevant to SMA therapy. Here, we review
evidence suggesting that the apparent selective vulnerability of motor neurons to SMN deficiency is relative rather
than absolute, signifying that therapies will need to be delivered systemically. We also consider evidence from mouse
models suggesting that SMN has its predominant action on the neuromuscular system in early postnatal life, during a
discrete phase of development. Data from these experiments suggest that the timing of therapy to increase SMN levels
might be crucial. The extent to which SMN is required for the maintenance of motor neurons in later life and whether
augmenting its levels could treat degenerative motor neuron diseases, such as amyotrophic lateral sclerosis (ALS),
requires further exploration.
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of drug or genetic-knockdown libraries prior to mammalian
validation (Westlund et al., 2004; Dimitriadi et al., 2010; Sleigh and
Sattelle, 2010). However, given that the essential elements of the
organization of neuromuscular function are conserved across 50
million years of evolution between mice and humans, mouse
models are probably best placed to answer fundamental questions
about SMN biology in the nervous system and the pathogenesis of
SMA.
Mouse models of SMA
Mouse models not only allow the dissection of biological processes
and assessment of gene and protein function in a mammalian
context, but are a useful preclinical tool for testing potential
therapies. Thus, an ideal mouse model of SMA should faithfully
recapitulate the cellular levels of SMN protein seen in patients in
order to preserve the relative selectivity for motor neuron
degeneration. Levels that are too low, such as can be found in
models involving tissue-specific ablation of SMN (Frugier et al.,
2000), simply induce cell death through disrupting the constitutive
cellular function of SMN, providing limited insight into motor
neuron vulnerability. The level of SMN expressed should also ideally
be titrated to ensure that the mouse lives long enough for
phenotypic analysis and therapeutic trials.
SMN2 transgenic mice
Mice possess a single Smn gene, which has 82% amino acid identity
with its human homolog and a similar expression pattern (Bergin
et al., 1997; DiDonato et al., 1997; Viollet et al., 1997). Homozygous
Smn deletion results in massive embryonic cell death before
implantation (Schrank et al., 1997). Heterozygous null mice lack a
marked clinical phenotype, although some reports suggest that
there is histologically detectable age-dependent loss of
neuromuscular integrity (Schrank et al., 1997; Jablonka et al., 2000;
Balabanian et al., 2007). A number of different strategies have been
employed to produce models that recapitulate the human genotype
(summarized in Table 1, with further information at
http://jaxmice.jax.org/list/ra1733.html). Two groups showed that
expression of a human SMN2 transgene on the Smn-null
background rescues lethality, and that transgene copy number
modifies severity (Hsieh-Li et al., 2000; Monani et al., 2000). Mice
carrying one or two copies of SMN2 (Smn–/–; SMN2+/+) are
indistinguishable from controls at birth but die before postnatal
day 7 (P7), and so are often referred to as the ‘severe’ model (and
will be referred to as such in the remainder of this review article).
Mice with four or more copies of SMN2 show complete rescue and
a normal lifespan, indicating that modestly enhanced expression
of full-length SMN from the SMN2 gene can prevent SMA,
confirming the idea that enhancing SMN2 expression is a potential
therapeutic strategy.
Modifications to the severe SMN2 mouse
Introduction of a second transgene, containing human SMN7
cDNA, into the severe model extends the lifespan from 6 to 13
days (Le et al., 2005). Initially generated to assess potential SMN7
toxicity (Kerr et al., 2000), the ‘SMN7’ model (Smn–/–; SMN2+/+;
SMN7+/+), which is still in effect a model of severe postnatal SMA,
is thought to be milder owing to the formation of heterologous
complexes between full-length SMN and SMN7, which might
stabilize SMN and affect its turnover. A number of other transgenes
containing point mutations in SMN1 (A2G, A111G) have also been
introduced into the severe model, resulting in increased lifespan
(Monani et al., 2003; Workman et al., 2009). However, unlike SMN2,
which generates a small amount of full-length protein, none of the
other transgenes rescue the embryonic lethality caused by Smn
deletion, indicating that some full-length SMN is an absolute
requirement for normal cellular function. Using a slightly different
approach to reduce Smn levels, a knock-in allele that disturbs
endogenous Smn splicing (Smn2B/–), similar to human SMN2, was
shown to result in more moderate severity, with a few animals living
longer than 1 month (Bowerman et al., 2009).
Cre-loxP models
Targeting of genomic DNA using the Cre-loxP recombination
system to perform deletion of Smn exon 7 from a conditional
(floxed) allele (SmnF7) should theoretically result in the sole
production of Smn7 and complete absence of full-length Smn in
the presence of Cre recombinase. Indeed, crossing these mice with
tissue-specific Cre mouse lines effectively produces complete
cellular knockdown of Smn in target tissues (Frugier et al., 2000;
Cifuentes-Diaz et al., 2001; Cifuentes-Diaz et al., 2002; Nicole et
al., 2003; Vitte et al., 2004). The complete absence of functional
Smn, which never occurs in patients, suggests that these models
provide only limited insights into the pathogenesis of SMA;
however, the absence of convincing data regarding whether
complete ablation of full-length Smn is achieved at a range of time
points precludes a definitive judgment. A more recently published
study in which endogenous Smn was conditionally depleted in
motor neuron progenitor cells, but importantly was not totally
ablated owing to the presence of transgenic human SMN2, provides
a potentially better model of the disease (Park et al., 2010).
However, the presence of normal levels of Smn in tissues other than
motor neurons seems to result in an unexpectedly mild phenotype,
hinting that the SMA phenotype might be more dependent on
systemic effects than previously appreciated.
The severe (SMN2 transgenic) mouse and its modification, the
SMN7 mouse, have become the most widely used SMA models
(Fig. 1). In the remainder of this Perspective, we discuss how these
and other mouse mutants have been used to address important
outstanding biological questions about SMA. We begin by
examining whether SMA is neurodegenerative or
neurodevelopmental in its essential character, and then move on
to discuss the evidence for absolute or relative motor neuronal
specificity in SMA, as well as the timing of SMN protein action
during development. Finally, we examine the controversy about
whether SMA is a disorder of splicing regulation or whether SMN
has a distinct neuronal function.
The nature of SMA: neurodegeneration or failure of
normal development?
The commonest and most severe form of SMA (Type I; previously
known as Werdnig-Hoffmann disease) begins prenatally or in the
early postnatal period, during a time of maturation and stabilization
of the neuromuscular system, the basic pattern of which is laid
down earlier in development. By contrast, the onset of muscle
weakness in at least some cases of other forms of SMA (late-
childhood and adult-onset SMA) occurs after the neuromuscular
dmm.biologists.org458
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Table 1. Mouse models of SMA
Genotype
Severity of
phenotypea Notes References
Smn–/– ++++ Death of embryo occurs prior to uterine implantation. (Schrank et al., 1997)
Smn+/– + Early acute loss of lumbar spinal cord motor neurons (~28% within 5 weeks), with
subsequent slowly progressive reduction over an extended time scale.
(Jablonka et al., 2000;
Balabanian et al.,
2007)
Smn–/–; SMN2(2Hung)+/+ + to +++ Transgene including human SMN2, SERF1 and part of NAIP; rescues embryonic
lethality of Smn–/–.
Transgene copy number correlates with disease severity, which ranges from
death within 1 week to normal survival.
(Hsieh-Li et al., 2000)
Smn–/–;
SMN2(89Ahmb)+/+
+ to +++ Transgene containing only the SMN2 locus, rescues Smn–/– embryonic lethality.
42/56 mice with one or two transgene copies were stillborn or died before 6
hours, with the remainder dying between 4-6 days.
Mice with eight copies of the transgene reach adulthood.
(Monani et al., 2000)
SmnF7/ 7; NSE-Cre+ ++ SmnF7/ 7 mice with Cre-loxP-mediated deletion of Smn exon 7 in neuronal tissue.
Mean lifespan: 25 days.
(Frugier et al., 2000;
Cifuentes-Diaz et al.,
2002)
SmnF7/ 7; HSA-Cre+ ++ SmnF7/ 7 mice with Cre-loxP-mediated deletion of Smn exon 7 in myoblasts and
post-mitotic fused myotubes of skeletal muscle.
Mean lifespan: 33 days.
(Cifuentes-Diaz et al.,
2001)
Smn+/–; Gemin2+/– + Mice with heterozygous deletion of Smn and Gemin2 display an accelerated loss
of motor neurons compared with Smn+/– mice.
(Jablonka et al., 2002)
Smn–/–;
SMN2(89Ahmb)+/–;
SMN1(A2G)+/–
+ Mean survival of mice with a single A2G transgene and one copy of SMN2 is 227
days, whereas mice homozygous for A2G are relatively indistinguishable from
controls.
(Monani et al., 2003)
SmnF7/F7; HSA-Cre+ + SmnF7/F7 mice with Cre-loxP-mediated deletion of Smn exon 7 in post-mitotic
fused myotubes of skeletal muscle.
Without heterozygous deletion of Smn exon 7 in all somatic cells, animals live for
a median of 8 months.
(Nicole et al., 2003)
SmnF7/F7; NSE-Cre+ ++ SmnF7/F7 mice with Cre-loxP-mediated deletion of Smn exon 7 in neuronal tissue.
Mean lifespan: 31±2 days.
(Ferri et al., 2004)
SmnF7/F7; Alfp-Cre+ ++++ SmnF7/F7 mice with Cre-loxP-mediated deletion of Smn exon 7 in hepatocytes.
Causes late embryonic lethality at E18.
Heterozygous deletion has no obvious effect.
(Vitte et al., 2004)
Smn–/–;
SMN2(89Ahmb)+/+;
SMN 7+/+
+++ Transgene containing human SMN 7, the predominant isoform produced by
SMN2; improves the phenotype of Smn–/–; SMN2+/+.
Mean lifespan: 13.3±0.3 days.
(Le et al., 2005)
Smn–/–; SMN2+/+;
SMN1(A111G)+/–
+ Transgene containing the SMN1 allele seen in Type I and II patients; improves
survival to over 1 year with no obvious phenotype.
(Workman et al., 2009)
Smn–/–; SMN2+/+;
SMN1(VDQNQKE)+/–
+++ Transgene containing SMN1 exons 1-6 with an additional motif; has little effect
on lifespan extension.
(Workman et al., 2009)
Smn2B/– ++ Smn transgene harboring three nucleotide substitutions within the exonic
splicing enhancer of exon 7.
Mean lifespan: 28 days.
(Bowerman et al., 2009)
Smn–/–; SMN2(N11)+/–;
SMN2(N46)+/–
+++ Mice with three copies of SMN2 were generated by crossing strains with two
(N11) and four (N46) copies.
Mean lifespan: 15.2±0.4 days.
(Michaud et al., 2010)
SmnF7/–;
SMN2(89Ahmb)+/+;
Olig2-Cre+
+ SmnF7/–; SMN2+/+ mice (i.e. Smn+/–; SMN2+/+) with Cre-loxP-mediated deletion of
Smn exon 7 in spinal cord motor neuron progenitor cells.
~70% of mutants survived to 12 months, yet were clearly distinguishable from
controls.
(Park et al., 2010)
Smn1tm1Cdid/tm1Cdid; CreEsr1
and Smn1tm2Cdid/tm2Cdid;
CreEsr1
 ++++ Inducible Smn alleles that mimic SMN2 splicing are homozygous embryonic
lethal (E12.5-E15.5) and normal when heterozygous.
In the presence of Cre recombinase, loxP-flanked neomycin (Neo) gene resistance
cassettes situated in Smn intron 7 are excised, producing full-length Smn.
When crossed with a tamoxifen-inducible Cre allele (CreEsr1), early embryonic
induction of full-length Smn by tamoxifen can rescue embryonic lethality.
(Hammond et al., 2010)
a+, mild; ++, moderate; +++, severe; ++++, embryonic lethal.
SmnF7/ 7 mice are Smn+/ 7, and SmnF7/F7 mice are Smn+/+.
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system has developed. Nevertheless, in these later-onset patients
it remains possible that the foundation for subsequent loss of
neuromuscular integrity and subsequent age-dependent motor
neuron degeneration is established in earlier development.
Primary motor neurons isolated from the lumbar spinal cord of
severe SMA mouse embryos at embryonic day 14 (E14) do not show
reduced survival in culture, but axon elongation, growth-cone size,
-actin dynamics and spontaneous excitability are all significantly
impaired (Rossoll et al., 2003; Jablonka et al., 2007). A similar
phenotype has also been observed in cultured sensory neurons
(Jablonka et al., 2006). Moreover, differentiation and neuritogenesis,
but not survival or growth, of neurospheres from the brains of
severe SMA mouse embryos is abnormal (Shafey et al., 2008).
However, direct neurophysiological recording from Smn-deficient
mouse motor neurons in culture does not show a functional deficit
(Zhang et al., 2010).
In contrast to the above observations from in vitro systems
showing abnormalities in embryonic motor neurons, the available
SMA mouse models have similar numbers of motor neurons in the
spinal cord at birth compared with their control littermates, and
are visibly indistinguishable from these mice, suggesting that gross
prenatal development is largely unaffected by Smn depletion
(Hsieh-Li et al., 2000; Monani et al., 2000; Le et al., 2005). No major
defects in axonal morphology or outgrowth were seen at various
embryonic stages in multiple different tissues of severe mutants
expressing GFP in motor neurons (Hb9-SMA mice) (McGovern et
al., 2008). There was, however, a significant increase in the number
of vacant synapses lacking motor axon input at E18 in intercostal
muscles (McGovern et al., 2008), and neuromuscular junction
(NMJ) neurofilament accumulation and an increased length of axon
terminals was observed in the phrenic nerve of SMN7 mice at
E18.5 (Kariya et al., 2009). Nonetheless, in a detailed study of the
NMJ in severe SMA mice at a pre-symptomatic stage (P1), there
were no detectable defects in motor axon patterning and branching,
NMJs were formed normally, and there were no significant changes
in gene expression in the spinal cord (Murray et al., 2010b).
Disruption of the NMJ is known to occur in a range of different
muscles during early and late symptomatic stages in postnatal
severe SMA mice (Murray et al., 2010a). Neuromuscular pathology
was found to be more pronounced in the predominantly slow-
twitch transversus abdominis muscle as well as the caudal band of
the fast-twitch levator auris longus in these mice (Murray et al.,
dmm.biologists.org460
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E10  E17 E18 E19 P0 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10  P16
Severe SMA mouse
SMNΔ7 mouse
Majority of mice living
past P1 die at ~P4-P6
Low levels of vacant NMJs in
intercostal muscles (E18)
Subtle NF abnormalities at the nerve
terminals of phrenic nerve axons (E18.5) Central synaptic defects and
thermoregulation deficiency (P4)
Motor axonal varicosities in many
muscles and signs of increased cell
death in the forebrain (from E10.5)
Weight loss, pre-synaptic NF
accumulation and heart defects (P2) Alternative splicing events and majordifferences in appearance (P7),
impaired neurotransmission (P7-P9)
and MN loss (P9)
Impaired snRNP assembly
and MN loss (P3)
Muscle tone
deficiency (P6)
Inability to self-right (P0)
NMJ pathology
in the TVA (P2)
Bone loss and severe
NMJ denervation (P5-P6)
Progressive deterioration
until death at P12-P16
NMJ maturation deficiency
with further pathology (P5)
Brain morphology defects and major protein
expression changes in hippocampus (P5)
Subtle motor cortex defects (P0),
but normal SC gene expression (P1)
Minor gene and exon-level
expression changes in the SC (P1)
Death
Death
Birth
Fig. 1. Timeline illustrating the major cellular and symptomatic events during the embryonic and postnatal development of severe (Smn–/–; SMN2+/+)
and SMN7 (Smn–/–; SMN2+/+; SMN7+/+) mouse models of SMA. MN, motor neuron; NF, neurofilament; NMJ, neuromuscular junction; SC, spinal cord; snRNP,
small nuclear ribonucleoprotein; TVA, transversus abdominis.
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2008; Ruiz et al., 2010), suggesting differential vulnerability of NMJs,
which has also been observed between the diaphragm and soleus
(Voigt et al., 2010). Similar progressive postnatal neuromuscular
pathology has been observed in a new SMA model that carries
three copies of SMN2 (Michaud et al., 2010) and in the SMN7
mouse (Kariya et al., 2008; Murray et al., 2008; Kong et al., 2009),
although the majority of pathology observed in SMN7 mice
resulted in modified neurofilament accumulation and functional
disruption at the NMJ rather than loss of presynaptic motor nerve
terminals. These presynaptic changes occurred in tandem with a
delay in developmental maturation of postsynaptic acetylcholine
receptors (Biondi et al., 2008; Kariya et al., 2008; Kong et al., 2009).
Alongside these morphological and functional changes at the
NMJ, longitudinal exon-level gene-expression studies in the spinal
cord of the SMN7 model showed an apparent failure of expression
of genes that cluster in postnatal developmental pathways (Bäumer
et al., 2009).
If SMN has distinct functions during the period of postnatal
neuromuscular development, this would have profound
implications for the timing of SMN replacement therapy.
Observations in mouse models of SMA suggest that NMJs can form
and function normally prior to the postnatal onset of disease
(Murray et al., 2010b), and that NMJ denervation precedes motor
neuron loss (Fig. 1) (Kariya et al., 2008; Murray et al., 2008; Kong
et al., 2009). Thus, the high levels of SMN seen during early
postnatal development, the window of developmental vulnerability
to SMN depletion and the perinatal onset of severe SMA all suggest
that the disease is related to postnatal maturation events in the
neuromuscular system (Bäumer et al., 2009; Murray et al., 2010b).
Is motor neuron specificity in SMA absolute or relative?
In contrast to evidence from mouse models of severe SMA, severe
infantile SMA in patients carrying only one or two copies of SMN2
can begin in utero and can be associated with extended involvement
of the peripheral nervous system, including demyelination,
inexcitability and axonal degeneration in sensory neurons
(Korinthenberg et al., 1997; Omran et al., 1998; Rudnik-Schöneborn
et al., 2003; Anagnostou et al., 2005). Moreover, it has been
recognized by neuropathologists for many years that specific
regions of the brain such as the thalamus show neuronal loss in
severe SMA patients, although this has been assumed to be
subclinical (Shishikura et al., 1983; Yohannan et al., 1991; Oka et
al., 1995; Hayashi et al., 1998; Araki et al., 2003; Ito et al., 2004).
The first major study of the involvement of non-motor nervous
tissue in SMA in mice reported that cell body size and number in
dorsal root ganglia (DRG) were normal, even at the late
symptomatic stage (P5) in the severe model, but that sensory
neurons cultured from E14 embryos showed reduced neurite
length and growth-cone size (Jablonka et al., 2006). Nerve endings
from E14 SMA mouse embryo footpads were much thinner than
those of controls and failed to reach their target destination in the
outer epidermal layer, although without displaying a difference in
number. Consistent with this, the latency to paw withdrawal in a
hot plate test was increased more than twofold in a new severe
model (Michaud et al., 2010). In the SMN7 mouse, no defect in
tactile sensory behavior was seen at early to mid disease stages, as
assessed by the clasping of paws in response to gentle stimulation
(Butchbach et al., 2007). Recently, sensory and motor synapses were
examined in Olig2-Cre mice (mild SMA model), which have
selectively depleted Smn levels in motor neuron progenitor cells
(Park et al., 2010). By staining sensory nerve terminals of the DRG,
the authors showed that adult mutant mice had a reduction in the
number and the mean area of synaptic boutons positioned against
cholinergic motor neurons. These defects were present by P7,
indicating that dysfunction in sensory neuronal projection onto
ventral horn cells develops at early stages of the disease. Central
synaptic defects that precede motor neuron loss have also recently
been reported in the spinal cord of SMN7 mice by P4 (Ling et
al., 2010; Mentis et al., 2011), which were more severe in
proprioceptive inputs onto motor neurons innervating proximal
muscles (Mentis et al., 2011). Olig2 expression is confined to spinal
motor neurons and oligodendrocytes, so the sensory neuron
defects seen in this Cre-loxP mouse model are unlikely to be caused
by Smn depletion in DRG proprioceptive neurons, and are perhaps
a direct consequence of pathological mechanisms triggered within
the motor neurons (Park et al., 2010). In addition to affecting motor
and sensory neurons, it appears that Smn reduction also affects
neuritogenesis and neurogenesis in the retinal neurons of Smn2B/–
mice (Liu et al., 2011).
Pathological changes in the brain have also been studied in
severe SMA mice. Increased cell death was observed in the
forebrain of E14.5 mutant embryos, with the telencephalon being
the most severely affected (Liu et al., 2010). This cell death was
independent of genetic background and was associated with a
greater than 70-fold increase in the amount of irregular nuclei.
Striking pathological foci of hyperchromatic cells containing cell
debris and condensed or shrinking nuclei were also observed. As
expected, cell death in the telencephalon was less severe at earlier
embryonic stages. Reduced Smn expression has also been shown
to affect perinatal development of the mouse brain, with a lower
brain weight and size at late symptomatic but not pre-
symptomatic stages (Wishart et al., 2010). Interestingly,
morphology varied between different brain regions, suggesting a
gradient of susceptibility to Smn deficiency and not merely an
overall reduction in brain volume as a reflection of smaller body
size. The primary motor cortex displayed a subtle progressive
decline in size from birth, whereas the primary somatosensory
cortex remained unaffected at all stages studied. The most striking
defects were observed in the hippocampus: a 50% reduction in
the size of the dentate gyrus in late-symptomatic SMA mice
compared with controls was associated with a reduction in cell
density, cell proliferation and postnatal neurogenesis (Wishart et
al., 2010). Proteomic analysis of the hippocampus of SMA mice
revealed numerous changes in the expression of proteins involved
in the regulation of cell proliferation, growth, migration and
development (Wishart et al., 2010). Notably, a microarray study
has also identified deficits in normal proliferative pathways in the
spinal cord of severe SMA mice, perhaps accounting for the
reduced number of proliferating cells in the central canal of the
spinal cord (Bäumer et al., 2009). Together, these studies implicate
cellular proliferation and postnatal developmental pathways in the
pathogenesis of SMA in both motor and non-motor regions of
the nervous system.
The presence of non-motor abnormalities in severe forms of
SMA suggests that there is a gradient of susceptibility to SMN
reduction in the nervous system, with motor neurons at one end
Disease Models & Mechanisms 461
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of a spectrum (Fig. 2). These observations, coupled with evidence
from mouse models indicating that dysfunction in non-
neuromuscular tissue might also contribute to the overall pathology
of SMA, have led to the development of the threshold hypothesis
(Box 1). An important consequence of this work is that it clearly
indicates that therapies aimed at replacing SMN, either by gene
delivery or by oligonucleotide-mediated alterations in SMN2
splicing, should be delivered systemically. Although it is currently
only a theoretical concern, it is possible that the correction of motor
neuron loss and subsequent improved survival would reveal effects
on other regions of the central nervous system (CNS) and other
organs in the long term, with major clinical consequences.
Is SMN a general survival factor for motor neurons?
Complete absence of SMN is lethal to all cells, but it remains unclear
whether SMN is required at the same levels, and at all stages of
development, in different cell types. Similarly, it remains unknown
whether SMN levels are required to be above a critical threshold
for motor neuron survival in adult life. If replacing SMN levels after
a specific developmental time point would have little or no effect
on the trajectory of disability, this has major implications for the
optimization of SMA therapy. Similarly, it is important to
understand whether therapies must achieve a maintenance level of
SMN into adulthood to preserve neuromuscular integrity in the
face of normal aging. Furthermore, if SMN can act as a survival
factor for motor neurons in adult life, it might serve as a therapeutic
target for other neuromuscular diseases, including amyotrophic
lateral sclerosis (ALS).
The onset of SMA is not infrequently reported to be rather
sudden, occurring over a period of days to weeks. Rapid decline in
motor function is then followed by a long period in which disease
progression is relatively slow (Sumner, 2007). A similar
phenomenon has been reported in the Olig2-Cre SMA mice, in
which Smn is selectively depleted in motor neurons (Park et al.,
2010). Although at birth these mice are indistinguishable from
controls, mutants rapidly develop functional defects in the first
week of life, some of which seemed to stabilize with age. These
periods of rapid, progressive decline with subsequent relative
stability suggest that there is a specific period of development
during which SMN depletion is most detrimental to motor
function. Consistent with this, Smn in the mouse is most highly
expressed in spinal cord and brain during embryonic and neonatal
development, after which time the levels are rapidly reduced and
then maintained at a residual level throughout life (Gabanella et
al., 2005). This mimics the situation in humans, in which expression
levels of SMN are high in fetal tissue compared with in postnatal
periods (Burlet et al., 1998).
Delivery of SMN using self-complementary adeno-associated
virus 9 (scAAV9) at different developmental stages in SMN7 mice
had little effect when administered at P10, and only marginally
increased survival when administered at P5. However, when
administered at P1, there was an unprecedented improvement in
lifespan to over 250 days at the time that the study was submitted
for publication, indicating that earlier Smn replacement leads to
better survival (Foust et al., 2010). This could be explained either
by a higher level of motor neuron transduction efficiency in P1
mice compared with older mice (Foust et al., 2009) or by the effect
of increased Smn levels being heavily dependent on the stage of
development. Other studies in which compounds have been
delivered at different stages support the latter view (Narver et al.,
2008; Butchbach et al., 2010), as does the recent finding that early
but not late embryonic restoration of Smn using two inducible Smn
alleles can rescue lethality (Hammond et al., 2010).
Interestingly, mouse models of differing severities show similar
degrees of motor neuron loss, perhaps indicating that the
developmental stage at which degeneration occurs is a key
determinant of disease progression. For instance, compared with
controls, severe SMA mice display an approximate 40% reduction
in spinal cord motor neuron number at P5, the late-symptomatic
stage (Monani et al., 2000), whereas Smn heterozygotes display a
40% loss at 6 months and a 54% loss at 1 year (Jablonka et al., 2000).
In a subsequent study of the heterozygous mice, a reduction of
lumbar motor neurons by 28% was reported at 5 weeks and by 30%
at 3 months, suggesting once again that there is an early period of
susceptibility in which there is greater degeneration of motor
neurons, followed by a period of relative stability (Balabanian et
al., 2007).
The comparatively high SMN protein levels in the spinal cord
during development and the apparent onset of SMA during a
restricted perinatal period suggest that the requirement for SMN
is temporally regulated in the nervous system. Nevertheless, there
is also evidence that SMN might exert positive effects on survival
later in life. Significant loss of facial and spinal motor neurons in
Smn-null heterozygotes has been observed to occur between 6 and
12 months (Jablonka et al., 2000). However, this seems to be
subclinical motor neuron loss, in keeping with the lack of a
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Fig. 2. The threshold hypothesis of SMA. There seems to be a differential
susceptibility of cell types and tissues to SMN reduction. Motor neurons are
most severely affected by SMN depletion and are thus at one end of a
vulnerability-resistance spectrum. As protein levels are further reduced,
additional tissues such as bone, heart and sensory neurons become affected,
while other cells and tissues remain unaffected. For example, at approximately
10-20% of normal SMN levels, as seen in Type I SMA patients, motor neurons
are severely affected, the heart and brain CNS show partial involvement,
whereas many organs remain relatively unaffected. See Box 1 for details.
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phenotype in 1 in 40 SMA carriers (those who only carry one copy
of SMN1) in the general human population (Pearn, 1978).
A reduction in Smn levels by 50% has also been shown to worsen
motor performance and survival of the SODG93A mouse model of
ALS, suggesting that SMN might indeed be constitutively required
throughout life (Turner et al., 2009). Furthermore, increasing SMN
levels to rescue the severe phenotype in early life has not
consistently prevented the ultimate development of a phenotype
and a reduced overall lifespan (Meyer et al., 2009; Passini et al.,
2010; Valori et al., 2010; Dominguez et al., 2011; Passini et al., 2011).
Is SMA a disorder of splicing regulation?
The best-characterized function of SMN is the assembly and
processing of snRNPs. The SMN complex, which includes Gemins
2-8 and Unrip, ensures the specific and efficient assembly of a stable
heptameric ring of Sm proteins (forming the Sm core) onto newly
exported small nuclear ribonucleic acids (snRNAs) (Pellizzoni,
2007). After further maturation steps, the resulting snRNPs are
exported into the nucleus and function in the removal of introns
from pre-mRNA transcripts in the process of splicing (Pellizzoni
et al., 2002). Depending on the class of intron removed, there are
two principal types of spliceosomal snRNP that are assembled by
the SMN complex: those found in the major spliceosome, which
processes almost all eukaryotic introns, and those that splice all
other introns as part of the minor spliceosome (Patel and Steitz,
2003). Mouse models provide an opportunity to address the
hypothesis, developed from in vitro studies, that snRNP assembly
is the crucial function of SMN that is relevant to the pathogenesis
of SMA.
The central role of SMN in such a fundamental cellular process
provides an adequate explanation as to why complete absence of
the protein is universally lethal. Why reduced SMN levels cause
such a specific effect on lower motor neurons remains the central
conundrum of SMA research. It is possible that motor neurons
have a greater constitutive requirement for snRNP assembly and
are thus more susceptible to defects in splicing, or that disturbed
splicing of a subset of neuron-specific genes triggers motor neuron
loss. Alternatively, SMN might have a distinct motor-neuron-
specific function, as suggested by the presence of SMN in protein
complexes in the axon that have a different makeup than the
canonical SMN complex that is involved in snRNP assembly
(Briese et al., 2005; Rossoll and Bassell, 2009).
The evidence for a tight linkage between SMA and functional
impairment of snRNP assembly is significant but as-yet
incomplete. SMA-causing SMN1 mutations have been shown to
affect the interaction of SMN with Sm proteins (Bühler et al., 1999;
Pellizzoni et al., 1999), and snRNP assembly activity is reduced
in SMA patient cells to an extent that is proportional to SMN
levels (Wan et al., 2005; Gabanella et al., 2007). The first study to
demonstrate a direct link between snRNP biogenesis and SMA
pathology showed that defects in Xenopus laevis or zebrafish
embryos that were caused by a reduction of SMN or Gemin2 can
be rescued by injection of purified snRNPs (Winkler et al., 2005).
However, a number of SMA-causing SMN1 mutations, including
one found in a Type I SMA patient, display no defect in snRNP
assembly activity (Shpargel and Matera, 2005) and, despite
impairment of snRNP synthesis, endogenous snRNP and snRNA
levels were found to be unaltered in patient-derived (Type I SMA)
fibroblasts, a chicken cell line and a severe Drosophila mutant,
all of which had severely reduced SMN levels (Wan et al., 2005;
Gabanella et al., 2007; Rajendra et al., 2007). Moreover, despite a
significant difference in lifespan between the severe and SMN7
models (~9 days), there is no difference in snRNP assembly
activity (Gabanella et al., 2007), suggesting that the difference in
disease severity is caused by differential effects on an additional
function of the Smn protein. It should be noted that snRNAs that
are not associated with Sm cores are unstable (Sauterer et al.,
1988), so snRNA levels are similar to snRNP levels.
Steady-state snRNA levels in spinal cord extracts of 3-day-old
severe SMA mice are also only marginally reduced in spite of a
tenfold decrease in snRNP assembly activity (Gabanella et al.,
2007). This apparent contradiction indicates that cells possess an
excess capacity to assemble snRNPs, such that reducing SMN
levels has only a modest effect. However, levels of a subset of
snRNAs belonging to the minor splicing pathway (U11 and U12)
were significantly reduced in the brain and spinal cord of severe
SMA mice (Gabanella et al., 2007). U11 snRNA levels were also
lowered in the kidney, suggesting that reduced SMN levels can
unevenly affect the profile of snRNPs in a tissue-specific manner.
This preferential reduction in minor snRNAs in the context of
reduced SMN levels has since been confirmed in a number of
different models and tissues (Zhang et al., 2008; Workman et al.,
2009).
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Box 1. The involvement of non-neuromuscular tissue
in SMA and the threshold hypothesis
There is evidence that cells and tissues outside of the nervous system are also
affected in SMA. Bone and heart complications have been reported in
numerous patients (Finsterer and Stöllberger, 1999; Kelly et al., 1999;
Felderhoff-Mueser et al., 2002; Khawaja et al., 2004; Bach, 2007; Khatri et al.,
2008; Rudnik-Schöneborn et al., 2008). Poor perfusion and autonomic
dysfunction have also been observed (Arai et al., 2005; Hachiya et al., 2005;
Araujo Ade et al., 2009). A similar picture is beginning to emerge in mouse
models. SMN has recently been implicated in bone remodeling and skeletal
pathogenesis in the severe model (Shanmugarajan et al., 2007; Shanmugarajan
et al., 2009), which, along with the SMN7 mouse, also displays cardiac defects
including bradycardia and arrhythmia (Bevan et al., 2010; Heier et al., 2010;
Shababi et al., 2010). Furthermore, numerous models display a vascular
necrosis of the extremities (Hsieh-Li et al., 2000; Meyer et al., 2009; Gogliotti et
al., 2010; Hua et al., 2010; Michaud et al., 2010; Riessland et al., 2010), and the
vagus cranial nerve in the severe mouse appears defasciculated, with less
distinct morphological boundaries (Liu et al., 2010). The pathological findings
in cells other than motor neurons, which are predominantly seen in more
severe cases, have led to the development of the threshold hypothesis. This
hypothesis proposes that there is a differential susceptibility of cells to SMN
depletion (Fig. 2), and that different cell types and tissues fall in different
positions within a vulnerability-resistance spectrum. At one extreme, motor
neurons seem to be the most sensitive cell type to reduced SMN levels. As
SMN levels are further reduced, the range of affected cells becomes greater, to
a point at which there is insufficient protein for survival of any cell type. It is
thus important that protein levels in animal models of SMA do not reach the
threshold at which there is universal cell degeneration, because such a model
will not be useful for dissecting the reasons why motor neurons are
particularly vulnerable. Together, these findings suggest that SMA is a
multisystem disorder; this has great significance for the development of new
treatments, because therapies will need to be delivered systemically for the
greatest chance of success. Moreover, improved understanding of this
differential susceptibility is likely to offer further insights into the function of
SMN in neurons.
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The correlation between disease severity and snRNP assembly
activity has been shown in a range of mouse models (Gabanella et
al., 2007; Workman et al., 2009). In mouse spinal cord, snRNP
biogenesis is most prominent in the CNS during embryogenesis
and early postnatal development, correlating with levels of Smn
(Gabanella et al., 2005). The spatiotemporal expression patterns of
Smn and Gemin2 are closely co-regulated, and the subclinical
motor neuron loss seen in Smn heterozygous mice is accelerated
in Smn+/–; Gemin2+/– heterozygotes, which is associated with a
reduction in snRNP assembly (Jablonka et al., 2001; Jablonka et al.,
2002).
It is clear that the formation of snRNPs is affected by SMN
reduction. However, the functional consequences of this disturbed
assembly and how this contributes to SMA pathology are much
less clear. If a failure of snRNP assembly is the pathological lesion
that leads to selective motor neuron death, this would be predicted
to cause dysfunctional splicing across a wide range of pre-mRNA
transcripts at or before disease onset, and also to result in ‘aberrant’
transcripts that are not normally seen in tissues in physiological
states. However, there is only an approximately twofold increase
in the error rate of splice-site pairing in phenotypically normal
fibroblasts from severe Type I SMA patients (Fox-Walsh and Hertel,
2009). In end-stage (P13) SMN7 mice, Zhang et al. used exon-
level microarrays to identify widespread tissue-specific splicing
abnormalities, even in histologically normal tissues such as the
kidney (Zhang et al., 2008). This curious finding suggests a lack of
congruence between splicing abnormalities and cellular pathology,
and, given that the mice assayed were moribund, might simply
reflect a non-specific response to tissue injury. A longitudinal study
of exon-level changes in the spinal cord of both severe and SMN7
mice at pre-symptomatic (P1), early-symptomatic (P7) and late-
symptomatic (P13) stages suggests that the vast majority of
alternative splicing events are actually a late feature of disease and
are thus unlikely to play a causative role in SMA pathology (Bäumer
et al., 2009). Only a small number of transcripts were altered
compared with control mice at the pre-symptomatic stage, and all
alterations involved a shift to known isoforms. Additionally, the
introns processed by the minor spliceosome were not preferentially
affected, as might be expected if the specific reduction of minor
spliceosomal snRNPs had a direct effect on splicing. The role of
the small number of genes that are alternatively spliced early on in
the disease, and a possible axon-specific function for SMN, should
be further assessed in SMA mouse models.
Conclusions
SMA is a devastating disorder of the nervous system that
predominantly affects very young children and has no available
treatment. A number of key questions about causative pathways
and disease pathology remain unresolved, and their clarification
will help both to improve our general understanding of the disease
mechanism but also crucially inform the development and
optimization of novel therapeutic strategies. An abundance of
studies have demonstrated that multiple mouse SMA models that
mimic the broad spectrum of disease seen in patients and that allow
conditional SMN expression are required to fully explore these
complex issues. Owing to the great progress in furthering our basic
biological understanding of SMA and the availability of appropriate
preclinical models, this disease has been highlighted by the NIH
and other funding bodies as being one of the neurogenetic diseases
that is closest to being cured. A wide range of different therapeutic
approaches – including viral-mediated gene delivery, small
molecules that upregulate SMN expression, and oligonucleotide-
mediated splicing modification – are now close to entering clinical
trials. As these therapies approach clinical translation there will
still be much to learn from mouse models about how to best apply
these therapies for the benefit of patients.
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